Acumen Pharmaceuticals, Inc. (ABOS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acumen Pharmaceuticals, Inc. (ABOS) trades at $2.69 with AI Score 24/100 (Grade F). Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease. Market cap: $163.25M, Sector: Healthcare.
Price live · AI analysis from May 7, 2026Analyst Coverage for ABOS: ABOS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ABOS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ABOS: 1/1 perspectives are bearish.
How is this calculated? →Acumen Pharmaceuticals, Inc. (ABOS) Healthcare & Pipeline Overview
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in Alzheimer's disease therapeutics. Their lead candidate, ACU193, a humanized monoclonal antibody targeting soluble amyloid-beta oligomers, is in Phase I clinical trials. The company aims to address a significant unmet need in the growing Alzheimer's treatment market.
What Is the Investment Thesis for ABOS?
Acumen Pharmaceuticals presents a focused investment opportunity within the Alzheimer's disease therapeutics market. The company's lead drug candidate, ACU193, targets soluble amyloid-beta oligomers, a distinct approach compared to plaque-targeting therapies. Successful Phase I clinical trial results could serve as a major catalyst, potentially leading to partnerships or further investment. The company's low beta of 0.21 suggests lower volatility compared to the broader market. However, the inherent risks of clinical-stage biopharmaceutical development, including trial failures and regulatory hurdles, must be considered. The company's market capitalization of $163.25M reflects both the potential and the risks associated with its single-asset pipeline. The absence of a dividend reflects the company's focus on reinvesting capital into research and development.
Based on FMP financials and quantitative analysis
ABOS Key Highlights
- Lead drug candidate ACU193 is in Phase I clinical trials, targeting soluble amyloid-beta oligomers.
- Market capitalization of $163.25M reflects the potential and risks associated with a single-asset pipeline.
- Beta of 0.21 indicates lower volatility compared to the broader market.
- Focused on a novel immunotherapy approach for Alzheimer's disease, differentiating it from plaque-targeting therapies.
- Headquartered in Newton, US, with 61 employees dedicated to Alzheimer's disease research and development.
Who Are ABOS's Competitors?
ABOS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| BIIB Biogen Inc. | $212.58 | -1.64% | $31.39B | 78 |
| VRTX Vertex Pharmaceuticals Incorporated | $529.59 | +0.29% | 135B | 99 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ABOS's Key Strengths?
- Novel approach targeting soluble amyloid-beta oligomers.
- Lead drug candidate in Phase I clinical trials.
- Experienced management team with expertise in Alzheimer's disease.
- Strong intellectual property protection.
What Are ABOS's Weaknesses?
- Single-asset pipeline.
- High risk associated with clinical-stage drug development.
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful clinical trial outcomes.
What Could Drive ABOS Stock Higher?
- Release of Phase I clinical trial data for ACU193.
- Potential initiation of Phase II clinical trials for ACU193.
- Research and development efforts to expand the pipeline with additional Alzheimer's therapies.
- Strategic partnerships with larger pharmaceutical companies.
What Are the Key Risks for ABOS?
- Financial-distress signal — its Altman Z-Score of -4.50 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for ACU193.
- Regulatory hurdles in obtaining FDA approval.
- Competition from other Alzheimer's disease therapies.
- Patent expiration for key technologies.
- Dependence on securing additional funding to support research and development.
What Are the Growth Opportunities for ABOS?
- Advancement of ACU193 through clinical trials: The successful completion of Phase I clinical trials and progression into Phase II and Phase III trials represents a significant growth opportunity for Acumen. Positive data demonstrating safety and efficacy could attract partnerships with larger pharmaceutical companies or further investment, potentially leading to accelerated development and commercialization. The timeline for this growth opportunity is dependent on clinical trial timelines, with potential milestones occurring within the next 2-5 years.
- Expansion of pipeline with additional Alzheimer's therapies: Acumen could leverage its expertise in amyloid-beta oligomer targeting to develop additional therapeutic candidates. This could involve exploring different antibody formats, delivery methods, or combination therapies. Expanding the pipeline would diversify the company's risk profile and create multiple opportunities for growth. The timeline for this growth opportunity is dependent on research and development efforts, with potential new candidates entering preclinical development within the next 3-5 years.
- Strategic partnerships with larger pharmaceutical companies: Acumen could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of ACU193 or other pipeline candidates. These partnerships could provide access to funding, expertise, and global distribution networks. The timing of such partnerships is uncertain but could occur at any point following positive clinical trial data.
- Expansion into diagnostic tools for early Alzheimer's detection: Acumen could leverage its expertise in amyloid-beta oligomers to develop diagnostic tools for early detection of Alzheimer's disease. This could involve developing biomarkers or imaging agents that can identify individuals at risk of developing Alzheimer's or those in the early stages of the disease. The market for early Alzheimer's detection is growing, driven by the increasing availability of disease-modifying therapies. The timeline for this growth opportunity is dependent on research and development efforts, with potential diagnostic tools entering clinical validation within the next 3-5 years.
- Acquisition by a larger pharmaceutical company: Given the significant unmet need and market potential for Alzheimer's disease therapies, Acumen could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its presence in this therapeutic area. A successful acquisition could provide Acumen's shareholders with a significant return on investment. The timing of such an acquisition is uncertain and dependent on market conditions and the company's progress in clinical development.
What Opportunities Does ABOS Have?
- Positive clinical trial data could lead to partnerships or acquisitions.
- Expansion of pipeline with additional Alzheimer's therapies.
- Development of diagnostic tools for early Alzheimer's detection.
- Growing market for Alzheimer's disease therapies.
What Threats Does ABOS Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other Alzheimer's disease therapies.
- Patent expiration.
What Are ABOS's Competitive Advantages?
- Proprietary technology targeting soluble amyloid-beta oligomers.
- Strong intellectual property protection for ACU193 and other pipeline candidates.
- Expertise in Alzheimer's disease research and development.
- Potential for first-in-class therapy targeting soluble amyloid-beta oligomers.
What Does ABOS Do?
Acumen Pharmaceuticals, Inc., founded in 1996 and headquartered in Charlottesville, Virginia, is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for Alzheimer's disease. The company's primary focus is on advancing ACU193, a humanized monoclonal antibody, through clinical trials. ACU193 is designed to selectively target soluble amyloid-beta oligomers (AβOs), which are believed to be a primary driver of Alzheimer's disease pathology. Unlike some other approaches that target amyloid plaques, Acumen's therapy aims to neutralize the toxic soluble oligomers, potentially offering a more effective treatment strategy. The company is currently in Phase I clinical development with ACU193, evaluating its safety, tolerability, and pharmacokinetic properties in healthy volunteers and patients with early Alzheimer's disease. Acumen's approach represents a novel immunotherapy strategy in the fight against Alzheimer's, a disease with a significant and growing global burden. With a focused pipeline and a commitment to scientific rigor, Acumen Pharmaceuticals seeks to address the critical unmet need for disease-modifying therapies in Alzheimer's disease.
What Products and Services Does ABOS Offer?
- Discovers and develops therapies for the treatment of Alzheimer's disease.
- Focuses on targeting soluble amyloid-beta oligomers (AβOs).
- Advances ACU193, a humanized monoclonal antibody, through clinical trials.
- Conducts Phase I clinical trials to evaluate the safety, tolerability, and pharmacokinetic properties of ACU193.
- Seeks to address the unmet need for disease-modifying therapies in Alzheimer's disease.
- Develops novel immunotherapy strategies for Alzheimer's.
How Does ABOS Make Money?
- Develops and patents novel therapeutic candidates for Alzheimer's disease.
- Conducts preclinical and clinical trials to evaluate the safety and efficacy of these candidates.
- Seeks regulatory approval from the FDA and other regulatory agencies.
- Potentially commercializes approved therapies directly or through partnerships with larger pharmaceutical companies.
What Industry Does ABOS Operate In?
Acumen Pharmaceuticals operates within the biotechnology sector, specifically targeting the Alzheimer's disease therapeutics market. This market is characterized by a high unmet need and significant growth potential, driven by an aging global population and increasing prevalence of Alzheimer's. The competitive landscape includes major pharmaceutical companies and smaller biotech firms, all vying to develop effective treatments. Key trends include the development of novel immunotherapy approaches, such as Acumen's, and a shift towards targeting earlier stages of the disease. Success in this market requires strong scientific expertise, significant capital investment, and the ability to navigate complex regulatory pathways.
Who Are ABOS's Key Customers?
- Patients diagnosed with Alzheimer's disease.
- Healthcare providers who treat patients with Alzheimer's disease.
- Pharmaceutical companies seeking to expand their Alzheimer's disease portfolios.
- Research institutions and organizations involved in Alzheimer's disease research.
FY2026 estForward Outlook
Wall Street analysts project Acumen Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-1.42.
ABOS Valuation & Market Position
With a $163.25M market cap, Acumen Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ABOS's quantitative score of 24/100 is below the peer average of 87/100.
Key Financial Metrics
Return on assets is -84.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -68.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -70.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Acumen Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.50 places it in the distress zone, a signal of elevated financial risk.
Company Profile
Acumen Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newton, US. The company is led by CEO Daniel J. O'Connell. ABOS has traded publicly since 2021.
ABOS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Acumen's focus on Alzheimer's treatment is gaining increased attention, reflecting a potential shift in market perception towards innovative solutions for neurodegenerative diseases. Think Biogen's Aduhelm approval, but with a potentially more targeted approach.
- Recent insider buying activity suggests confidence in the company's future prospects, aligning with the belief that those closest to the company see value. This is similar to when Elon Musk buys more Tesla stock.
- Positive community sentiment indicates growing optimism regarding Acumen's clinical trial progress and its potential to address a significant unmet medical need. This buzz can drive momentum.
- The company's approach targeting toxic soluble amyloid-beta oligomers is viewed favorably within the scientific community, suggesting a differentiated strategy compared to other Alzheimer's therapies.
Bear Case
- The Alzheimer's drug development space is littered with failures, and Acumen faces significant clinical and regulatory hurdles. Remember the issues with Axsome's AXS-05?
- Despite positive sentiment, the long and expensive clinical trial process poses substantial risks, and negative trial results could severely impact the stock.
- Community sentiment can be fickle, and negative news or trial setbacks could quickly shift the narrative, leading to a rapid decline in investor confidence.
- Competition in the Alzheimer's space is intense, with larger pharmaceutical companies pursuing alternative approaches, potentially overshadowing Acumen's efforts. This is like smaller EV companies competing with Tesla.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ABOS Latest News
-
Earnings Scheduled For May 12, 2026
benzinga · May 12, 2026
-
Earnings Scheduled For August 12, 2025
benzinga · Aug 12, 2025
ABOS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ABOS.
Price Targets
Wall Street price target analysis for ABOS.
ABOS MoonshotScore
What does this score mean?
The MoonshotScore rates ABOS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Daniel J. O'Connell
CEO
Daniel J. O'Connell serves as the CEO of Acumen Pharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at various biotechnology companies, contributing to the advancement of novel therapies. O'Connell's expertise spans across multiple therapeutic areas, including neurology and immunology. His educational background includes advanced degrees in science and business, providing him with a strong foundation for leading a clinical-stage biopharmaceutical company.
Track Record: Under Daniel J. O'Connell's leadership, Acumen Pharmaceuticals has focused on advancing ACU193 through Phase I clinical trials. He has overseen the company's strategic direction, focusing on targeting soluble amyloid-beta oligomers as a novel approach to treating Alzheimer's disease. O'Connell has also been instrumental in securing funding and building a strong team to support the company's research and development efforts. His leadership is crucial for navigating the complexities of clinical-stage drug development and positioning Acumen for future success.
Acumen Pharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does Acumen Pharmaceuticals, Inc. do?
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Alzheimer's disease. Their primary focus is on ACU193, a humanized monoclonal antibody currently in Phase I clinical trials. ACU193 targets soluble amyloid-beta oligomers (AβOs), believed to be a key driver of Alzheimer's pathology. Unlike therapies targeting amyloid plaques, Acumen's approach aims to neutralize these toxic soluble oligomers, potentially offering a more effective treatment. The company's goal is to address the significant unmet need for disease-modifying therapies in Alzheimer's.
What do analysts say about ABOS stock?
Analyst coverage of Acumen Pharmaceuticals, Inc. (ABOS) is still emerging, reflecting its clinical-stage status. Key valuation metrics are closely tied to the success of ACU193's clinical trials. Growth considerations center on the potential market for Alzheimer's disease therapies and Acumen's ability to secure partnerships or funding. Analyst consensus will likely shift based on clinical trial data and regulatory milestones. Investors should conduct their own due diligence and consider the inherent risks of biopharmaceutical investments.
What are the main risks for ABOS?
The main risks for Acumen Pharmaceuticals, Inc. include the potential failure of ACU193 in clinical trials, regulatory hurdles in obtaining FDA approval, and competition from other Alzheimer's disease therapies. As a clinical-stage company with a single-asset pipeline, Acumen is highly dependent on the success of ACU193. The company also faces the risk of patent expiration and the need to secure additional funding to support its research and development efforts. These risks are inherent in the biopharmaceutical industry and should be carefully considered by investors.
What are the key factors to evaluate for ABOS?
Acumen Pharmaceuticals, Inc. (ABOS) holds an AI score of 24/100 (low). Not financial advice.
How frequently does ABOS data refresh on this page?
ABOS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ABOS's recent stock price performance?
Acumen Pharmaceuticals, Inc. (ABOS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel approach targeting soluble amyloid-beta oligomers. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ABOS overvalued or undervalued right now?
Valuing Acumen Pharmaceuticals, Inc. (ABOS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ABOS?
Before investing in Acumen Pharmaceuticals, Inc. (ABOS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- This is not investment advice. Conduct your own due diligence.